![Fouzia Laghrissi-Thodes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fouzia Laghrissi-Thodes
Direktor/Vorstandsmitglied bei
MINERVA NEUROSCIENCES, INC.
Vermögen: - $ am 30.09.2026
Profil
Dr. Fouzia Laghrissi-Thodes, MD, is a Chief Executive Officer & Director at DalCor Pharmaceuticals Canada, Inc., an Independent Director at Minerva Neurosciences, Inc. and an Independent Director at Smart Immune SAS. She is on the Board of Directors at DalCor Pharmaceuticals Canada, Inc., Minerva Neurosciences, Inc., Cellaïon SA and Smart Immune SAS. Dr. Laghrissi-Thodes was previously employed as a VP-Cardiovascular & Metabolism Therapy by AstraZeneca PLC and a Chief Executive Officer by ZS Pharma, Inc. She also served on the board at Nuro Corp.
She received her doctorate degree from Université François-Rabelais de Tours.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 03.06.2026 | 0 ( -.--% ) | - $ | 30.09.2026 |
Aktive Positionen von Fouzia Laghrissi-Thodes
| Unternehmen | Position | Beginn |
|---|---|---|
| MINERVA NEUROSCIENCES, INC. | Direktor/Vorstandsmitglied | 18.05.2015 |
DalCor Pharmaceuticals Canada, Inc.
 DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Develops precision treatments for cardiovascular disease | Vorstandsvorsitzender | 03.04.2018 |
Smart Immune SAS
 Smart Immune SAS BiotechnologyHealth Technology Develops T-cell progenitor-based cell and gene therapy | Direktor/Vorstandsmitglied | - |
Promethera Therapeutics SA
 Promethera Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops novel therapies | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Fouzia Laghrissi-Thodes
| Unternehmen | Position | Ende |
|---|---|---|
| ZS PHARMA INC | Vorstandsvorsitzender | - |
Nuro Corp.
 Nuro Corp. Packaged SoftwareTechnology Services Develops neurological communication software solutions | Direktor/Vorstandsmitglied | - |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Ausbildung von Fouzia Laghrissi-Thodes
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
42
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
ZS Pharma, Inc.
 ZS Pharma, Inc. BiotechnologyHealth Technology Develops develop new treatments of kidney and liver diseases | Health Technology |
Université François-Rabelais de Tours
 Université François-Rabelais de Tours Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Minerva Neurosciences, Inc.
 Minerva Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes drugs to treat patients suffering from central nervous system diseases | Health Technology |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Develops precision treatments for cardiovascular disease | Health Technology |
Nuro Corp.
Nuro Corp. Packaged SoftwareTechnology Services Develops neurological communication software solutions | Technology Services |
Smart Immune SAS
Smart Immune SAS BiotechnologyHealth Technology Develops T-cell progenitor-based cell and gene therapy | Health Technology |
Promethera Therapeutics SA
Promethera Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops novel therapies | Commercial Services |
